Clinical Trials Logo

Clinical Trial Summary

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. The phycocyanin (PC), a biliprotein pigment and an important constituent of the blue-green alga Spirulina platensis, has been reported to possess significant antioxidant and radical-scavenging properties, offering protection against oxidative stress. Study hypothesis is that phycocyanin may give protection against oxaliplatin-induced neuropathy in the treatment of gastro intestinal cancers including oesogastric, colo-rectal and pancreatic cancers. This trial will be a randomised placebo-controlled study.

Clinical Trial Description

The phycocyanin used in this protocol (Phycocare®) will be 5 times more concentrated than the Spirulysat (food supplement commercialized by Algosource). It will be administrated during Oxaliplatin based chemotherapy and 3 months after oxaliplatin stopped. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05025826
Study type Interventional
Source Nantes University Hospital
Contact Christèle LE GOUILL JAIJARAT, MD
Phone 02 53 48 28 35
Email christè[email protected]
Status Not yet recruiting
Phase N/A
Start date November 5, 2021
Completion date November 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04618809 - Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer N/A
Recruiting NCT02668380 - An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer N/A
Completed NCT03121807 - Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer N/A
Recruiting NCT04358354 - Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer Phase 3
Not yet recruiting NCT05024812 - Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Phase 1/Phase 2
Completed NCT01099527 - A Trial of RAD001/Capecitabine in Refractory Gastric Cancer Phase 1/Phase 2
Completed NCT00253370 - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT02002195 - Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Recruiting NCT03154983 - The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer Phase 2
Not yet recruiting NCT04263870 - Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 2
Active, not recruiting NCT01359397 - Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT04739202 - Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Phase 2
Active, not recruiting NCT03409848 - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma Phase 2
Terminated NCT01528501 - Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) Phase 2
Recruiting NCT03751761 - GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study Phase 1/Phase 2
Active, not recruiting NCT03614013 - Resistance to Immunotherapy in Gastric Cancer
Terminated NCT02076594 - Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer Phase 3
Completed NCT00632268 - Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer Phase 2
Recruiting NCT04166721 - WaKING: Wnt and checKpoint INhibition in Gastric Cancer Phase 1/Phase 2